Energenesis Biomedical CO.,LTD. (6657.TW)

TWD 57.1

(-0.7%)

Market Cap (In TWD)

5.05 Billion

Revenue (In TWD)

7.15 Million

Net Income (In TWD)

-260.38 Million

Avg. Volume

1.24 Million

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
45.9-63.9
PE
-18.84
EPS
-3.03
Beta Value
0.575
ISIN
-
CUSIP
-
CIK
-
Shares
88494000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jen-yi Chiu
Employee Count
-
Website
https://www.energenesis-biomedical.com
Ipo Date
2023-06-01
Details
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, which include western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.